Hemostemix’s patented ACP-01 and NCP-01 autologous cell therapies demonstrate potential to extend brain–computer interface functional lifespan beyond one year by modulating inflammatory responses, stimulating angiogenesis through VEGF and IL-8 signaling, and enhancing synaptogenesis and neural plasticity. This approach aims to improve implant integration and signal fidelity for advanced neuroprosthetic applications.
Key points
ACP-01 secretes CXCL8, VEGF, and angiogenin to recruit NK cells and CD34+ progenitors, driving angiogenesis and inflammation suppression at BCI sites.
NCP-01 utilizes CXCR4-mediated homing to implant regions, differentiates into neuronal and glial cells, and supports synaptogenesis for improved signal integration.
Combined intracerebrospinal delivery of ACP-01 and NCP-01 addresses inflammatory scarring and neural loss, potentially extending BCI functional lifespan and maintaining signal fidelity.
Why it matters:
This dual-cell approach could transform neuroprosthetic interfaces by significantly extending implant longevity, enhancing signal quality, and improving patient outcomes.
Q&A
What are ACP-01 and NCP-01 precursors?
How does ACP-01 promote angiogenesis around implants?
Why is inflammation reduction critical for BCI durability?
What role does NCP-01 play in neural integration?
Read full article
Academy
Brain-Computer Interfaces and Cellular Therapies for Implant Longevity
Introduction
Brain-Computer Interfaces (BCIs) are devices that connect the human brain to external hardware, translating neural signals into commands for computers or prosthetics. BCIs have transformed assistive technologies for paralysis, communication, and control of robotic limbs. Yet, typical implants fail within 6–12 months due to inflammation, scarring, and neuronal loss at the implant site.
Autologous Cell Therapies: ACP-01 and NCP-01
Autologous cell therapies use a patient’s own blood-derived cells to promote tissue repair without triggering immune rejection. Hemostemix has developed two complementary products:
- ACP-01 (Angiogenic Cell Precursors): Enriched for CD34+ progenitors, these cells secrete proteins such as CXCL8 (interleukin-8), VEGF (vascular endothelial growth factor), and angiogenin. They reduce inflammation, recruit natural killer cells, and stimulate new blood vessel growth (angiogenesis) around the implant.
- NCP-01 (Neural Cell Precursors): These cells express receptors like CXCR4, which guide them to the implant site via chemokine gradients. There, they differentiate into neurons and supporting glial cells, forming new synaptic connections and enhancing neural plasticity.
Mechanisms Supporting Implant Longevity
Both therapies work together to address key failure modes:
- Inflammation Reduction: ACP-01 releases anti-inflammatory signals that shift macrophages to a healing M2 state, reducing scarring and preventing glial encapsulation of electrodes.
- Angiogenesis: New blood vessels formed by ACP-01 improve oxygen and nutrient delivery, essential for tissue health and electrode functionality.
- Neural Integration: NCP-01 cells build new synaptic networks around the implant, lowering impedance and boosting signal quality.
- Neuroprotection: Combined paracrine factors from both cell types activate NF-κB and other survival pathways, protecting neurons from apoptosis.
Relevance to Longevity Science
Implant longevity is a key challenge in longevity science and neurotechnology. Extending BCI lifespan aligns with goals to maintain cognitive and motor functions in aging populations or patients with neurodegenerative diseases. Autologous approaches minimize immune reactions and offer personalized solutions, making them attractive for long-term therapeutic applications.
Future Directions and Considerations
Further research will focus on preclinical and clinical trials to validate safety, dosing, and delivery routes for ACP-01 and NCP-01. Engineers and biologists will need to optimize implant materials and cell dosing schedules. Addressing regulatory requirements is critical for translation to human therapies. As the field advances, combining cell therapies with biomaterials and closed-loop feedback systems could enable robust, lifelong neural interfaces.
Key Takeaways
Autologous angiogenic and neural cell precursors provide a promising strategy to extend BCI functionality, representing a convergence of cell therapy, neuroengineering, and longevity science.
